Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.60 |
| ▸ | EBP | Q15125 | 3/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | SCN1A | P35498 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anipamil SCHEMBL31479919 | 0.90 | SIGMAR1 (0.69) | SIGMAR1EBPABCB1CYP3A4TSHR | |
| Anipamil SCHEMBL247837 | 0.90 | SIGMAR1 (0.69) | SIGMAR1EBPABCB1CYP3A4TSHR | |
| Anipamil SCHEMBL9177433 | 0.89 | SIGMAR1 (0.67) | SIGMAR1EBPABCB1CYP3A4TSHR | |
| Anipamil SCHEMBL7199272 | 0.89 | SIGMAR1 (0.67) | SIGMAR1EBPABCB1CYP3A4TSHR | |
| SCHEMBL24224796 | 0.87 | SIGMAR1 (0.60) | SIGMAR1EBPABCB1CYP3A4TSHR | |
| SCHEMBL10710335 | 0.82 | MAOB (0.46) | SIGMAR1EBPABCB1CYP3A4TSHR | |
| SCHEMBL7273494 | 0.82 | EBP (0.50) | SIGMAR1EBPABCB1CYP3A4TSHR | |
| SCHEMBL10452644 | 0.81 | ABCB1 (0.78) | SIGMAR1EBPABCB1CYP3A4TSHR | |
| SCHEMBL10452643 | 0.81 | ABCB1 (0.78) | SIGMAR1EBPABCB1CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL10454045 | 0.81 | MEN1 (0.78) | SIGMAR1EBPABCB1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-101919822-B | Tablet with improved combination properties and preparation method thereof | ZHONG SHUGUANG | 2013-10-23 | — | — | CN | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-0639986-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1995-03-01 | — | — | EP | claimed |
| WO-1993023082-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1993-11-25 | — | — | WO | claimed |
| EP-3485881-B1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | HARVARD COLLEGE (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| CN-1038838-C | Chiral nitriles, their preparation and their use for the manufacture of verapamil and analogues | CHIROSCIENCE LTD (GB) | 1998-06-24 | — | — | CN | disclosed |
| EP-0721448-B1 | CHIRAL NITRILES, THEIR PREPARATION AND THEIR USE FOR THE MANUFACTURE OF VERAPAMIL AND ANALOGUES | CHIROSCIENCE LTD (GB) | 1998-03-11 | — | — | EP | disclosed |
| CN-1131941-A | Chiral nitriles, their preparation and their use for the manufacture of verapamil and analogues | CHIROSCIENCE LTD (GB) | 1996-09-25 | — | — | CN | disclosed |
| EP-0639986-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993023082-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5246705-A | Thermoplastic or crosslinked elastomer | CYGNUS THERAPEUTIC SYSTEM (US) | 1993-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | SIGMAR1 411/4885EBP 4385/4885ABCB1 1390/4885 |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CACNA1B, TRPV1, ORAI1 | SIGMAR1 1504/4885EBP 2294/4885ABCB1 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.